Li Yanjuan, Kuang Lifen, Huang Beihui, Liu Junru, Chen Meilan, Li Xiaozhe, Gu Jingli, Yu Tongyong, Li Juan
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
Biomedicines. 2025 Jan 9;13(1):145. doi: 10.3390/biomedicines13010145.
: Patients with multiple myeloma (MM) who have a suboptimal response to induction therapy or early relapse are classified as functional high-risk (FHR) patients and have been shown to have a dismal prognosis. The aim of this study was to establish a predictive nomogram for patients with non-transplanted FHR MM. : The group comprised 215 patients in our center between 1 January 2006 and 1 March 2024. To identify independent risk factors, univariate and multivariate logistic regression analyses were performed, and a nomogram was constructed to predict non-transplant FHR MM. To evaluate the nomogram's predictive accuracy, we utilized bias-corrected AUC, calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC). : Multivariate logistic regression demonstrated that younger age at onset, a higher proportion of LDH (more than 220 U/L), pattern A + C of M protein decline patterns, a lower proportion of patients with induction treatment efficacy than VGPR, and those undergoing maintenance therapies were independent risk factors for patients with non-transplanted FHR MM. The AUC scores for the training and internal validation groups were 0.940 (95% CI 0.893-0.986) and 0.978 (95% CI 0.930-1.000). DCA and CIC curves were utilized to further verify the clinical efficacy of the nomogram. : We developed a nomogram that enables early prediction of non-transplant FHR MM patients. Younger age at onset, LDH ≥ 220 U/L, an A + C pattern of M-protein decline, and induction therapy efficacy not reaching VGPR are more likely to be FHR MM patients. Patients who do not undergo maintenance therapy are prone to early progression or relapse.
对诱导治疗反应欠佳或早期复发的多发性骨髓瘤(MM)患者被归类为功能高危(FHR)患者,其预后较差。本研究旨在为未接受移植的FHR MM患者建立一个预测性列线图。:该组包括2006年1月1日至2024年3月1日期间在我们中心的215例患者。为了确定独立危险因素,进行了单因素和多因素逻辑回归分析,并构建了一个列线图来预测未移植的FHR MM。为了评估列线图的预测准确性,我们使用了偏差校正AUC、校准曲线、决策曲线分析(DCA)和临床影响曲线(CIC)。:多因素逻辑回归表明,发病年龄较小、乳酸脱氢酶(LDH)比例较高(超过220 U/L)、M蛋白下降模式为A + C型、诱导治疗疗效低于VGPR的患者比例以及接受维持治疗的患者是未移植FHR MM患者的独立危险因素。训练组和内部验证组的AUC分数分别为0.940(95%CI 0.893 - 0.986)和0.978(95%CI 0.930 - 1.000)。利用DCA和CIC曲线进一步验证了列线图的临床疗效。:我们开发了一个列线图,能够早期预测未移植的FHR MM患者。发病年龄较小、LDH≥220 U/L、M蛋白下降呈A + C模式以及诱导治疗疗效未达到VGPR的患者更有可能是FHR MM患者。未接受维持治疗的患者容易早期进展或复发。